For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Sales and marketing | - | 12,779 | ||
| Total revenue | 75,128 | 26,284 | ||
| Research and development | 186,829 | 167,259 | ||
| Sales, general and administrative | 83,231 | 72,711 | ||
| Depreciation, amortization, and impairment | 22,171 | 90,850 | ||
| Total operating expenses | 292,231 | 343,599 | ||
| Loss from operations | -217,103 | -314,766 | ||
| Interest income | 28,329 | 38,473 | ||
| Grants and incentives | 13,890 | 13,620 | ||
| Other (note 15) | -2,711 | 62,278 | ||
| Total other income | 39,508 | 114,371 | ||
| Loss before income tax | -177,595 | -200,395 | ||
| Income tax recovery | -31,183 | -37,538 | ||
| Net loss | -146,412 | -162,857 | ||
| Foreign currency translation adjustment | 144 | -2,658 | ||
| Comprehensive loss | -146,268 | -165,515 | ||
| Basic EPS | -0.49 | -0.55 | ||
| Diluted EPS | -0.49 | -0.55 | ||
| Basic Average Shares | 298,707,082 | 294,327,532 | ||
| Diluted Average Shares | 298,707,082 | 294,327,532 | ||
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)